Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy

Urology

Volumn 50, Issue 5, 1997, Pages 733-739

  Blute, Michael L ^a   Bostwick, David G ^a   Bergstralh, Erik J ^a   Slezak, Jeff M ^a   Martin, Sandra K ^a   Amling, Christopher L ^a   Zincke, Horst ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0030692608     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00450-0     Document Type: Article

References (14)

1. Blute ML, Bostwick DG, Seay TM, Martin SK, Slezak JM, Bergstralh EJ, and Zincke H: Pathologic staging of prostate cancer: impact of margin status. Cancer (in press).
2. Bostwick DG, Myers RP, and Oesterling JE: Staging of prostate cancer. Semin Surg Oncol 10: 60-72, 1994.
3. 1 prostatic adenocarcinoma: significance of nuclear DNA ploidy pattern studied by flow cytometry. Mayo Clin Proc 63: 103-112, 1988.
4. Sakr WA, Wheeler TM, Blute M, Bodo M, Calle-Rodriguez R, Henson DE, Mostofi FK, Seiffert J, Wojno K, and Zincke H: Staging and reporting of prostate cancer - sampling of the radical prostatectomy specimen. Cancer 78: 366-368, 1996.
5. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 152: 1826-1830, 1994.
6. Catalona WJ, and Stein AJ: Staging errors in clinically localized prostatic cancer. J Urol 127: 452-456, 1982.
7. Villers A: Extracapsular tumor extension in prostatic cancer: pathways of spread and implications for radical prostatectomy, in Stamey TA (Ed): Monographs in Urology. Montverde, Florida, Medical Directions Publishing, vol 15, No 4.
8. Epstein JI, Carmichael MJ, Partin AW, and Walsh PC: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow-up. J Urol 149: 1478-1481, 1993.
9. Partin AW, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Serum PSA after anatomic radical prostatectomy. Urol Clin North Am 20: 713-725, 1993.
10. Stein A, DeKernion JB, Smith RB, Dorey F, and Patel H: Prostate-specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 147: 942-946, 1992.
11. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, and Wein A: A multivariate analysis of clinical and pathological factors that predict for prostate-specific antigen failure after radical prostatectomy for prostate cancer. J Urol 154: 131-138, 1995.
12. Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, and Zincke H: Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 42: 283-291, 1993.
13. Ohori M, Wheeler TM, Kattan MW, Goto Y, and Scardino PT: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154: 1818-1824, 1995.
14. Soloway MS, Roohollah S, Wajsman Z, McLeod D, Wood DP Jr, and Puras-Baez A, for the Lupron Depot Neoadjuvant Prostate Cancer Study Group: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMO) prostate cancer. J Urol 154: 424-428, 1995.